GlycoMimetics, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2003-01-01

Employees: 51

Market Cap: $11.6M

Website: http://www.glycomimetics.com

Clinical Trials

Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease

Phase 3

Terminated

Conditions: Sickle Cell Anemia
Sickle Cell Disease
Sickle Cell Disorders
Pain Crisis
Vaso-occlusive Crisis

Interventions: Drug: Rivipansel

First Posted Date: 2015-05-04

Last Posted Date: 2021-02-10

Lead Sponsor: GlycoMimetics Incorporated

Target Recruit Count: 154

Registration Number: NCT02433158

Locations: 🇺🇸
University of Maryland Medical System, Baltimore, Maryland, United States
🇺🇸
The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
🇺🇸
Johns Hopkins Medicine, Baltimore, Maryland, United States

and more 93 locations

Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML

Phase 1

Completed

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: GMI-1271
Drug: Mitoxantrone
Drug: Etoposide
Drug: Idarubicin
Drug: Cytarabine

First Posted Date: 2014-12-03

Last Posted Date: 2019-05-17

Lead Sponsor: GlycoMimetics Incorporated

Target Recruit Count: 91

Registration Number: NCT02306291

Locations: 🇺🇸
University of Michigan, Ann Arbor, Ann Arbor, Michigan, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of California, Davis Comprehensive Cancer Center, Sacramento, California, United States

and more 5 locations

Phase I Study to Assess Safety and Pharmacokinetics of GMI-1271 in Healthy Adult Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Placebo
Drug: Enoxaparin Sodium (Lovenox®)
Drug: GMI-1271

First Posted Date: 2014-10-22

Last Posted Date: 2018-02-27

Lead Sponsor: GlycoMimetics Incorporated

Target Recruit Count: 32

Registration Number: NCT02271113

Locations: 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Rivipansel With rHuPH20 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Rivipansel
Drug: Placebo

First Posted Date: 2014-08-15

Last Posted Date: 2020-06-18

Lead Sponsor: GlycoMimetics Incorporated

Target Recruit Count: 27

Registration Number: NCT02217917

Locations: 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium

Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease

Phase 3

Completed

Conditions: Anemia, Sickle Cell

Interventions: Other: Placebo
Drug: Rivipansel

First Posted Date: 2014-07-10

Last Posted Date: 2020-06-22

Lead Sponsor: GlycoMimetics Incorporated

Target Recruit Count: 345

Registration Number: NCT02187003

Locations: 🇺🇸
Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida, United States
🇺🇸
The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
🇺🇸
Children's Healthcare of Atlanta Aflac Cancer and Blood Disorders Center, Atlanta, Georgia, United States

and more 135 locations

Placebo-controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of GMI-1271 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Adult Subjects

Interventions: Drug: GMI-1271
Drug: Placebo

First Posted Date: 2014-06-20

Last Posted Date: 2018-02-27

Lead Sponsor: GlycoMimetics Incorporated

Target Recruit Count: 28

Registration Number: NCT02168595

Locations: 🇺🇸
Celerion, Lincoln, Nebraska, United States

A Study to Evaluate the Effect of IV Doses of GMI-1070 on Qtc Intervals in Healthy African-American Adult Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Rivipansel

First Posted Date: 2013-09-13

Last Posted Date: 2020-06-18

Lead Sponsor: GlycoMimetics Incorporated

Target Recruit Count: 48

Registration Number: NCT01941511

Locations: 🇺🇸
Pfizer Investigational Site, San Antonio, Texas, United States

Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis

Phase 2

Completed

Conditions: Vaso-occlusive Crisis
Sickle Cell Disease
Pain Crisis

Interventions: Drug: Placebo
Drug: GMI-1070

First Posted Date: 2010-05-10

Last Posted Date: 2020-05-13

Lead Sponsor: GlycoMimetics Incorporated

Target Recruit Count: 81

Registration Number: NCT01119833

Locations: 🇺🇸
Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸
The Johns Hopkins School of Medicine, Baltimore, Maryland, United States
🇺🇸
University of California, Davis Medical Center, Sacramento, California, United States

and more 19 locations

Study of Intravenous GMI-1070 in Adults With Sickle Cell Disease

Phase 1

Completed

Conditions: Sickle Cell Disease

Interventions: Drug: GMI-1070

First Posted Date: 2009-06-02

Last Posted Date: 2020-05-11

Lead Sponsor: GlycoMimetics Incorporated

Target Recruit Count: 15

Registration Number: NCT00911495

Locations: 🇺🇸
Duke Comprehensive Sickle Cell Center, Durham, North Carolina, United States
🇺🇸
Children's Hospital & Research Center Oakland, Oakland, California, United States
🇺🇸
University of California at Davis, CCRC, Sacramento, California, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy